Homepage Top Section1

Nuvectis secured worldwide rights, outside specified Asian territories, to develop, manufacture and commercialise Haisco’s drug candidates HSK42360 and HSK39297. Haisco will receive $40m in upfront and near-term payments,

Executives from both organisations, including LG AI Research head Woohyung Lim and D&D Pharmatech CEO Seulki Lee, attended the event to formalise the partnership. The project focuses on

The approval covers patients aged 12 years and older with inhibitors, as well as children aged six to 11 years, with or without inhibitors. Hympavzi is approved for

The collaboration aims to accelerate hit identification for these companies through a fee-for-success approach. It will combine OpenBench’s AI-based discovery platform with Concept Life Sciences’ expertise in medicinal

The deal covers the European Union, Iceland, Liechtenstein, Norway, Switzerland, the UK, and the Middle East and North Africa (MENA) region. Idefirix is used to desensitise adult patients

The approval covers adults and adolescents in the European Union (EU) who weigh at least 35kg and have haemophilia A (factor VIII deficiency) with factor VIII inhibitors, or

The round was led by Thrive Capital, with participation from existing investors Alphabet and GV, as well as new investors CapitalG, MGX, Temasek, and the UK Sovereign AI

The approval process was accelerated after Partner Therapeutics received the FDA Commissioner’s National Priority Voucher. Bizengri has already received breakthrough therapy and orphan drug designations for this indication.

The designation recognises the potential of RTx-015 to address significant unmet medical needs in patients with severe retinal degeneration. It advances the therapy’s regulatory support following a regenerative